We are live on ! Find out more

AYTU BioPharma

AYTU

Market cap $21M

1.93 USD

+0.03

1.58%

At close Updated Oct 26, 4:00 PM EDT

1 day

1.58%

5 days

-2.03%

1 month

-11.06%

3 months

-6.31%

6 months

-24.61%

Year to date

-30.32%

1 year

-12.67%

5 years

-95.95%

10 years

-99.99%

About: Aytu BioPharma Inc is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. It has single operating segment. Its product portfolio includes EXXUA, ADHD Portfolio, Pediatric Portfolio, and Other. Majority of revenue comes from ADHD Portfolio. It has presence in United States.

Employees: 76

Healthcare Drug Manufacturers - Specialty & Generic

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 20%

Neutral 80%

Negative 0%

Zacks Investment Research

Elite Pharmaceuticals vs. Aytu: Which CNS Stock Is the Better Buy?

ELTP and AYTU have different CNS portfolios, growth drivers and valuations, but which pharmaceutical stock looks better positioned? Let's dive in.

Elite Pharmaceuticals vs. Aytu: Which CNS Stock Is the Better Buy?

Aytu BioPharma, Inc. (AYTU) Q4 2026 Earnings Call Transcript

Aytu BioPharma, Inc. (AYTU) Q4 2026 Earnings Call Transcript

Aytu BioPharma, Inc. (AYTU) Q4 2026 Earnings Call Transcript

Zacks Investment Research

Aytu BioPharma, Inc. (AYTU) Reports Q4 Loss, Beats Revenue Estimates

Aytu BioPharma, Inc. (AYTU) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.26 per share a year ago.

Aytu BioPharma, Inc. (AYTU) Reports Q4 Loss, Beats Revenue Estimates

Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results

Fourth quarter fiscal 2026 net revenue increased 6.4% to $16.1 million from $15.1 million in the prior-year quarter Fourth quarter fiscal 2026 Adjusted EBITDA of $0.5 million EXXUA net revenue of $6.6 million in fiscal 2026, including $3.9 million in the fourth quarter, following full commercial launch during third quarter fiscal 2026 EXXUA fourth quarter fiscal 2026 total prescriptions were 3,323, up approximately 138% from 1,398 in third quarter fiscal 2026 $26.3 million cash balance at June 30, 2026 Company to host conference call and webcast today, September 22, 2026, at 4:30 p.m. Eastern time DENVER, CO / ACCESS Newswire / September 22, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced operational and financial results for the fiscal 2026 full year and fourth quarter.

Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results

Aytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026

DENVER, CO / ACCESS Newswire / September 16, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will report its operational and financial results for its fiscal 2026 full year and fourth quarter, after the market close on Tuesday, September 22, 2026. The Company has scheduled a conference call and webcast that same day, Tuesday, September 22, 2026, at 4:30 p.m.

Aytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026

Zacks Investment Research

New Strong Sell Stocks for July 20th

ACR, AEM and AYTU have been added to the Zacks Rank #5 (Strong Sell) List on July 20, 2026.

New Strong Sell Stocks for July 20th

Zacks Investment Research

New Strong Sell Stocks for July 16th

AYTU, CAMP and CRC have been added to the Zacks Rank #5 (Strong Sell) List on July 16, 2026.

New Strong Sell Stocks for July 16th

Aytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026

DENVER, CO / ACCESS Newswire / June 1, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced that it will be participating in a Fireside Q&A hosted by Lake Street Capital Markets at the Planet MicroCap Las Vegas 2026 Investor Conference Powered by MicroCapClub on Wednesday, June 17, 2026, at 10:30 a.m. Pacific time at the Bellagio Resort & Hotel.

Aytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026

Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

DENVER, CO / ACCESS Newswire / May 18, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2026 Investor Conference, taking place virtually on Thursday, May 28, 2026. Company Webcast The webcast presentation will take place at 9:15 a.m.

Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

Aytu BioPharma, Inc. (AYTU) Q3 2026 Earnings Call Transcript

Aytu BioPharma, Inc. (AYTU) Q3 2026 Earnings Call Transcript

Aytu BioPharma, Inc. (AYTU) Q3 2026 Earnings Call Transcript

See News Rankings

Price charts implemented using Lightweight Charts™